Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EREVA: BNT162b2 Vaccine Response in Immunocompromised Adults
NCT04952766Phase 4Completed
- Sponsor
- Centre Hospitalier Régional d'Orléans
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Centre Hospitalier Régional d'Orléans. Primary endpoint: Protective humoral response at 2 months. Started Mar 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04952766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952766.